LT3191120T - Il-17 antagonistų panaudojimas struktūrinio pažeidimo progresavimui slopinti, sergant psoriaziniu artritu - Google Patents

Il-17 antagonistų panaudojimas struktūrinio pažeidimo progresavimui slopinti, sergant psoriaziniu artritu

Info

Publication number
LT3191120T
LT3191120T LTEPPCT/IB2015/056871T LTIB2015056871T LT3191120T LT 3191120 T LT3191120 T LT 3191120T LT IB2015056871 T LTIB2015056871 T LT IB2015056871T LT 3191120 T LT3191120 T LT 3191120T
Authority
LT
Lithuania
Prior art keywords
antagonists
progression
inhibit
psoriatic arthritis
structural damage
Prior art date
Application number
LTEPPCT/IB2015/056871T
Other languages
English (en)
Lithuanian (lt)
Inventor
Shephard Mpofu
Hanno Richards
Gregory LIGOZIO
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3191120(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3191120T publication Critical patent/LT3191120T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
LTEPPCT/IB2015/056871T 2014-09-10 2015-09-08 Il-17 antagonistų panaudojimas struktūrinio pažeidimo progresavimui slopinti, sergant psoriaziniu artritu LT3191120T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
LT3191120T true LT3191120T (lt) 2024-07-25

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2015/056871T LT3191120T (lt) 2014-09-10 2015-09-08 Il-17 antagonistų panaudojimas struktūrinio pažeidimo progresavimui slopinti, sergant psoriaziniu artritu

Country Status (22)

Country Link
US (2) US11278618B2 (cg-RX-API-DMAC7.html)
EP (2) EP4406969A3 (cg-RX-API-DMAC7.html)
JP (4) JP2017528465A (cg-RX-API-DMAC7.html)
KR (2) KR20230170796A (cg-RX-API-DMAC7.html)
CN (4) CN115944734A (cg-RX-API-DMAC7.html)
AU (2) AU2015313827C1 (cg-RX-API-DMAC7.html)
BR (1) BR112017003332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2960754A1 (cg-RX-API-DMAC7.html)
DK (1) DK3191120T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981697T3 (cg-RX-API-DMAC7.html)
FI (1) FI3191120T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240921T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067081T2 (cg-RX-API-DMAC7.html)
LT (1) LT3191120T (cg-RX-API-DMAC7.html)
MX (1) MX2017003216A (cg-RX-API-DMAC7.html)
PL (1) PL3191120T3 (cg-RX-API-DMAC7.html)
PT (1) PT3191120T (cg-RX-API-DMAC7.html)
RS (1) RS65851B1 (cg-RX-API-DMAC7.html)
RU (1) RU2697383C2 (cg-RX-API-DMAC7.html)
SI (1) SI3191120T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400285T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016038538A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2960754A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
CA3001260A1 (en) 2015-10-27 2017-05-04 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies
TW201842933A (zh) * 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
WO2019040230A1 (en) * 2017-08-23 2019-02-28 Eli Lilly And Company TREATMENT OF GENITAL PSORIASIS
CA3080665A1 (en) * 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17) antagonists
EP3980065A4 (en) * 2019-06-04 2023-07-05 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIAL ARTHRITIS WITH ANTI-IL23 SPECIFIC ANTIBODY
KR102576258B1 (ko) 2019-12-05 2023-09-11 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PT1963368E (pt) 2005-12-13 2012-09-14 Lilly Co Eli Anticorpos anti-il-17
WO2007117749A2 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008156865A2 (en) 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
UA103499C2 (ru) 2008-09-29 2013-10-25 Рош Глікарт Аг Антитело против интерлейкина-17 (ил-17) человека и его применение
JP5537740B2 (ja) * 2010-10-08 2014-07-02 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
EP4116325A1 (en) * 2010-11-05 2023-01-11 Novartis AG Methods of treating rheumatoid arthritis using il-17 antagonists
WO2012082573A1 (en) * 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
RU2014125071A (ru) * 2011-11-21 2015-12-27 Новартис Аг Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
CA2960754A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Also Published As

Publication number Publication date
EP4406969A2 (en) 2024-07-31
AU2018201410A1 (en) 2018-03-22
MX2017003216A (es) 2017-05-23
AU2015313827C1 (en) 2018-08-30
KR20170045240A (ko) 2017-04-26
HUE067081T2 (hu) 2024-09-28
ES2981697T3 (es) 2024-10-10
AU2015313827A1 (en) 2017-02-16
JP2021152021A (ja) 2021-09-30
PL3191120T3 (pl) 2024-08-26
JP2023109973A (ja) 2023-08-08
CN113069542A (zh) 2021-07-06
RU2017107501A3 (cg-RX-API-DMAC7.html) 2019-03-12
SMT202400285T1 (it) 2024-09-16
JP7288927B2 (ja) 2023-06-08
US20170281762A1 (en) 2017-10-05
HRP20240921T1 (hr) 2024-10-11
EP4406969A3 (en) 2024-11-27
FI3191120T3 (fi) 2024-07-10
CA2960754A1 (en) 2016-03-17
CN115944734A (zh) 2023-04-11
CN107073110A (zh) 2017-08-18
KR20230170796A (ko) 2023-12-19
US11278618B2 (en) 2022-03-22
RS65851B1 (sr) 2024-09-30
RU2017107501A (ru) 2018-10-10
EP3191120A1 (en) 2017-07-19
AU2015313827B2 (en) 2018-02-15
BR112017003332A2 (pt) 2017-11-28
DK3191120T3 (da) 2024-07-15
JP7591092B2 (ja) 2024-11-27
JP2025024104A (ja) 2025-02-19
CN115957326A (zh) 2023-04-14
WO2016038538A1 (en) 2016-03-17
US20220313818A1 (en) 2022-10-06
EP3191120B1 (en) 2024-04-10
JP2017528465A (ja) 2017-09-28
RU2697383C2 (ru) 2019-08-13
PT3191120T (pt) 2024-07-16
SI3191120T1 (sl) 2024-10-30

Similar Documents

Publication Publication Date Title
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
HUE067081T2 (hu) Il-17 antagonisták alkalmazása strukturális károsodás progressziójának gátlására arthritis psoriaticában szenvedõ betegekben
GB201416102D0 (en) Impovements In or Relating To Shower Rods
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
IL251904B (en) Apilimod for use in the treatment of melanoma
GB201702982D0 (en) Improvements in or relating to centralisers
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
GB201809100D0 (en) Improvements in or relating to showers
PT3137622T (pt) Métodos para reduzir o declínio da capacidade vital
GB201705271D0 (en) Technology to facilitate and promote the use of environmentally-friendly transport
ZA201702488B (en) Improvements in or relating to connecting devices
HUE044801T2 (hu) Adelmidrol alkalmazása epitheliális mûködési zavarok kezelésében
GB201416463D0 (en) Improvements in or relating to temporary structures
GB2545716B (en) Improvements in or relating to the separation of radon
GB201419593D0 (en) Improvements in or relating to connecting devices
UA28633S (uk) Кутова оздоба до пам'ятника намогильного
ZA201408464B (en) Composition for the use in treatment of asthma
GB201415704D0 (en) Improvements in or Relating to Storage
GB201415702D0 (en) Improvements in or relating to storage
GB201415705D0 (en) Improvements in or Relating to Storage
GB201404391D0 (en) Novel compositions having use in therapy
GB201406072D0 (en) Improvements in or relating to storage
GB201406078D0 (en) Improvements in or relating to storage
GB201412345D0 (en) Improvements in and relating to devices